An immune therapy approach that was on the fringes of cancer therapy is suddenly the hottest trend in cancer drug development. Research by Arlene Sharpe, the George Fabyan Professor of Comparative Pathology at HMS; Keith Flaherty, associate professor of medicine at Massachusetts General Hospital; and F. Stephen Hodi and Gordon Freeman, both associate professors of medicine at the Dana-Farber Cancer Institute; is cited.
